Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

In vitro activity of telithromycin against Gram-negative bacterial pathogens.

D Felmingham1, D J Farrell

  • 1G.R. Micro Ltd, London NW1 3ER, UK. d.felmingham@grmicro.co.uk

The Journal of Infection
|July 6, 2005
PubMed
Summary

The ketolide antibiotic telithromycin shows strong activity against key Gram-negative respiratory pathogens like Haemophilus spp. and Moraxella catarrhalis. It offers potential as an alternative empirical therapy for community-acquired respiratory tract infections (RTIs).

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CPHLN recommendations for the laboratory detection of Shiga toxin-producing <i>Escherichia coli</i> (O157 and non-O157).

Canada communicable disease report = Releve des maladies transmissibles au Canada·2019
Same author

Gepotidacin (GSK2140944) <i>In Vitro</i> Activity against Gram-Positive and Gram-Negative Bacteria.

Antimicrobial agents and chemotherapy·2017
Same author

<i>In Vitro</i> Activity of Gepotidacin (GSK2140944) against Neisseria gonorrhoeae.

Antimicrobial agents and chemotherapy·2017
Same author

Plate augmentation for femoral nonunion: more than just a salvage tool?

Archives of orthopaedic and trauma surgery·2015
Same author

Wedge effect following intramedullary hip screw fixation of intertrochanteric proximal femur fracture.

Archives of orthopaedic and trauma surgery·2015
Same author

Antimicrobial activity of solithromycin against serotyped macrolide-resistant Streptococcus pneumoniae isolates collected from U.S. medical centers in 2012.

Antimicrobial agents and chemotherapy·2015

Area of Science:

  • Microbiology
  • Pharmacology
  • Infectious Diseases

Background:

  • Community-acquired respiratory tract infections (RTIs) pose a significant public health challenge.
  • Novel antimicrobial agents are needed to combat resistant bacterial strains.
  • Telithromycin, a ketolide antibiotic, has demonstrated broad-spectrum activity.

Purpose of the Study:

  • To evaluate the in vitro antibacterial activity of telithromycin.
  • To assess its efficacy against Gram-negative respiratory pathogens and commensal bacteria.
  • To determine its potential role in treating community-acquired RTIs.

Main Methods:

  • Bacterial isolates were collected from clinical samples and patients with RTIs globally.
  • Telithromycin susceptibility testing was performed following Clinical and Laboratory Standards Institute (CLSI) guidelines.

Related Experiment Videos

  • Results were interpreted using established CLSI breakpoints.

    • Main Results:

    • Telithromycin exhibited potent activity against Haemophilus spp., Neisseria spp., Bordetella pertussis, Legionella pneumophila, and Moraxella catarrhalis.
    • Activity was low against Acinetobacter spp., Enterobacteriaceae spp., Vibrio spp., Campylobacter jejuni, Aeromonas hydrophila, Plesiomonas shigelloides, and Pseudomonas aeruginosa.
    • Minimal activity was observed against Gram-negative non-respiratory pathogens and commensal bacteria.

    Conclusions:

    • Telithromycin effectively covers important Gram-negative respiratory tract pathogens.
    • It demonstrates limited activity against Gram-negative non-respiratory pathogens and commensal bacteria.
    • These findings support telithromycin's use as an alternative empirical therapy for community-acquired RTIs.